Co-Diagnostics announced on February 24, 2020, that it had received regulatory clearance to sell its COVID-19 tests in the European Community. Then on April 6, 2020, the company announced that it had received emergency use authorization for its tests from the U.S. Food and Drug Administration (“FDA”). Finally, on May 14, 2020, after the company continued to uphold its statements about the success of its test in its first quarter results, public reports began to circulate that questioned the company’s claims of 100% accuracy as a result of the company being hesitant to participate in U.S.-based testing. Later in the day, the U.S. FDA publicly stated that no COVID-19 test is 100% accurate. The company’s share price fell $5.06 on this news, or over 22%, to close at $17.07 per share on May 15, 2020, thereby injuring investors.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048